Omvoh (mirikizumab) — A Lilly Medicine

Dosing

For adults with moderately to severely active CD1

Indication-optimized dosing to meet the unique needs of CD1

START WITH INFUSIONS EVERY 4 WEEKS FOR 3 DOSES IN TOTAL

Induction Phase

CD: 900 mg per infusiona
MAINTENANCE WITH SUBCUTANEOUS INJECTIONS EVERY 4 WEEKS STARTING AT WEEK 12

Maintenance Phase

CD: 1 × 100 mg injection +
1 × 200 mg injection (in any order)
  • Initially intravenous infusion, then subcutaneous maintenance injections every 4 weeks, starting at Week 12.1
  • Patients can administer Omvoh with ease and convenience through prefilled pens for maintenance dosing.1

Omvoh is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject after training in proper technique.1

aPreparation of 3 × 300 mg per IV infusion dose for at least 90 minutes.

CD=Crohn's disease; IV=intravenous; Q4W=every 4 weeks; SC=subcutaneous; UC=ulcerative colitis.

1. Omvoh EUSPC FEB 2025

2. Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404(10470):2423–2436. Available from: https://doi.org/10.1016/S0140-6736(24)01762-8.

3. Barnes EL, Sands BE, D'Haens G, Hisamatsu T, Kelly CR, Lu N, et al. Long-term efficacy and safety of mirikizumab following 104 weeks of continuous treatment for Crohn's disease: results from the VIVID-2 open-label extension study. Presented at: Crohn's & Colitis Congress (CCC); February 6–8, 2025; San Francisco, CA.